Eloxx Pharmaceuticals annual operating margin
2010
2012
2013
2014
2024
Eloxx Pharmaceuticals Operating Margin Growth & History (ELOX)
Eloxx Pharmaceuticals's operating margin was −38.81% for fiscal 2024.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −38.81% | — |
| 2014 | 2014-06-30 | −5,019.95% | +54456.97 pp |
| 2013 | 2013-06-30 | −59,476.92% | −56771.15 pp |
| 2012 | 2012-06-30 | −2,705.76% | — |
| 2010 | 2010-06-30 | −3,461.80% | — |
Eloxx Pharmaceuticals quarterly operating margin
Q2.12
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2012 | 2011-12-31 | −728.07% | — |
Eloxx Pharmaceuticals operating margin trends
Between the periods ended 2010-06-30 and 2024-12-31, Eloxx Pharmaceuticals's operating margin increased from −3,461.80% to −38.81%, a change of +3422.99 percentage points. The latest reported quarter, Q2 2012, shows −728.07%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
